HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].

Abstract
In vitro drug sensitivity of clinically isolated bacteria against prulifloxacin (PUFX), which is a new quinolone, was investigated, and the antibacterial activity and susceptibility rate at clinical breakpoint were compared with those of norfloxacin, ofloxacin (OFLX), ciprofloxacin, tosufloxacin, fleroxacin, sparfloxacin and levofloxacin (LVFX). The following results were obtained. 1) PUFX showed a broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. 2) MIC80 of PUFX was 0.25 and 1 microgram/ml, against methicillin susceptible Staphylococcus aureus and Streptococcus pneumoniae, respectively and below 0.125 microgram/ml against Gram-negative Enterobacteriaceae. MIC90 of PUFX against Pseudomonas aeruginosa, which has MIC not exceeding 4 micrograms/ml to OFLX, was 0.5 microgram/ml. 3) PUFX was judged as active against the bacteria under the criteria proposed presented by "the Sensitivity Determination Committee for Antibiotics, Japan Society of Chemotherapy: Break Point for Respiratory Infectious Diseases and Sepsis". It is suggested that the sensitivity of each bacterial species to PUFX was high. 4) From the correlation analysis of MIC, PUFX was shown to have two to eight times higher antibacterial acitivity than LVFX for Citrobacter freundii, Serratia marcescens and Pseudomonas aeruginosa. 5) PUFX showed potent short-time bactericidal activity against S. aureus and P. aeruginosa.
AuthorsM Inoue, A Kuga, S Kaieda, M Hosaka, H Kitasato, Y Sato, R Okamoto, T Eda, K Hoshino, I Seto
JournalThe Japanese journal of antibiotics (Jpn J Antibiot) Vol. 53 Issue 9 Pg. 593-608 (Sep 2000) ISSN: 0368-2781 [Print] Japan
PMID11214999 (Publication Type: Comparative Study, English Abstract, Journal Article)
Chemical References
  • Anti-Infective Agents
  • Dioxolanes
  • Fluoroquinolones
  • Piperazines
  • Quinolones
  • Levofloxacin
  • Ofloxacin
  • ulifloxacin
  • prulifloxacin
Topics
  • Anti-Infective Agents (pharmacology)
  • Bacteria (drug effects, isolation & purification)
  • Dioxolanes (pharmacology)
  • Drug Resistance, Microbial
  • Fluoroquinolones
  • Humans
  • Levofloxacin
  • Ofloxacin (pharmacology)
  • Piperazines (pharmacology)
  • Quinolones (pharmacology)
  • Respiratory Tract Infections (microbiology)
  • Sepsis (microbiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: